Isradipine Versus Placebo in Early Parkinson Disease: A Randomized Trial

RCT evaluating isradipine 5mg bd vs placebo in 336 patients with early Parkinson’s Disease (<3yrs) did not show a statistically significant change in the Unified Parkinson's Disease Rating Scale parts I to III score between the 2 groups between baseline and 36 months of treatment

SPS commentary:

A related editorial discusses the findings, suggesting that it is possible that the isradipine dose in this study may have been insufficient to engage the target calcium channels associated with neuroprotective effects.


Annals of Internal Medicine

Resource links: